NEW YORK (GenomeWeb) – Owlstone Medical said today it has signed a service agreement with AstraZeneca to study breath-based biomarkers for asthma and COPD.

Under the terms of the agreement, Owlstone will give AstraZeneca access to its Breath Biopsy Services to help the pharmaceutical company identify breath-based biomarkers as well as classification algorithms for the conditions, with the aim of identifying disease phenotypes and the best treatments for those phenotypes.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).